Market Access | Getting therapies in patients' hands

News

MFN model for Medicaid revealed by CMS

The Trump administration has released details of a most-favoured nation (MFN) drug pricing programme for medicines provided by Medicaid.

Market Access

Policy in Focus: Trump’s MFN deals, FDA vouchers, and the go...

Policy experts Alice Valder Curran and Elizabeth Jungman of Hogan Lovells weigh in on Trump's MFN deals, FDA vouchers, and the government shutdown.

News

GLP-1s feature in second batch of national priority vouchers

GLP-1 drugs for weight loss, cancer, and rare diseases feature among the latest crop of medicines awarded priority vouchers by the FDA.

News

Company representatives with President Trump in the Oval Office

Novo, Lilly sign MFN pricing deal with Trump administration

The pricing agreement between Novo Nordisk and Eli Lilly and the Trump administration on GLP-1 drugs for diabetes and obesity has arrived.

Market Access

patient data on a screen accessed by HCP

HES data: The UK’s powerful source of real-world evidence

HES data not only supports the effective management of health and care services, but it can also power clinical research and innovation.

Market Access

Sponsored

The stealth market access strategy that’s quietly making man...

There is an under-the-radar market access strategy that some manufacturers have implemented, but many others remain unaware of.

News

FDA clears Roche, Lilly Alzheimer's blood test

A blood test developed by Roche and Eli Lilly that could help diagnose patients with Alzheimer's more quickly has been approved by the FDA.

News

Kelun gets world-first approval for TROP2 ADC

Kelun-Biotech has picked up another world-first approval for its TROP2-targeting ADC sac-TMT in non-small cell lung cancer.

News

MFN model for Medicaid revealed by CMS

The Trump administration has released details of a most-favoured nation (MFN) drug pricing programme for medicines provided by Medicaid.

News

GLP-1s feature in second batch of national priority vouchers

GLP-1 drugs for weight loss, cancer, and rare diseases feature among the latest crop of medicines awarded priority vouchers by the FDA.

Press Releases

News

Immunocore's rare eye cancer drug backed by NICE

Patients in England with a rare form of eye cancer will be able to access Kimmtrak, a TCR therapy from Immunocore, after NICE changes its position.

News

2019-Gene-Therapy-Muscular-Dystrophy_ProgFeature_IMG

Solid Biosciences acquires AavantiBio, conducts $75 million ...

The life sciences company Solid Biosciences is merging with the privately-held gene therapy company AavantiBio in a

Views & Analysis

Market Access

Policy in Focus: Trump’s MFN deals, FDA vouchers, and the go...

Policy experts Alice Valder Curran and Elizabeth Jungman of Hogan Lovells weigh in on Trump's MFN deals, FDA vouchers, and the government shutdown.

Market Access

HES data: The UK’s powerful source of real-world evidence

HES data not only supports the effective management of health and care services, but it can also power clinical research and innovation.

Deep Dive

Market Access

JCA readiness: How to prepare for success in the new EU HTA ...

Market Access

From market access to real-world patient access: Closing the...

Market Access

Demystifying market access: Inside the complex journey from ...

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Webinars

IQVIA Webinar on Innovative Medicines Fund

Sponsored

Innovative Medicines Fund and the opportunity for ICSs to mo...

Webinars

Sponsored

Medical Informatics and Rare Disease: a bridge between two w...

With more than 6,000 different diseases comprising the rare disease (RD) landscape, connecting patients and practitioners with the expertise needed to achieve th

Webinars

Sponsored

ICSs - an opportunity to improve Patient & Market Access at ...

With the new Health and Care Bill edging ever closer to receiving Royal Assent, life sciences companies in the UK are preparing to navigate the most significant piece of NHS legislation in

Podcasts

Market Access

Policy in Focus: Trump’s MFN deals, FDA vouchers, and the go...

Policy experts Alice Valder Curran and Elizabeth Jungman of Hogan Lovells weigh in on Trump's MFN deals, FDA vouchers, and the government shutdown.

Market Access

pharmaphorum podcast Episode 210 - Neal Masia

Smoothing a contract pathway through uncertainty: In convers...

Today's podcast with Entity Risk's Neal Masia includes insights on the 340B Program, PBMs, and risk-based contracts.

Market Access

Frontiers Health limited podcast series, Pilar Fernández Hermida

FH25: Commercialising Health Tech and Deeptech, with Pilar F...

In a new episode of our limited Frontiers Health series of the pharmaphorum podcast, we speak with commercial strategy expert Pilar Fernández Hermida.

Video

Market Access

Interview at BIO 2025 with Paul Romness and Farah Ahmad

Global unity in the face of uncertainty, with Paul Romness a...

Market Access

Interview at BIO 2025 with Kyle Touchstone and Laura Rowley

Biotech opportunities in North Carolina, with Kyle Touchston...

From BIO 2025: Kyle Touchstone, director of Economic Development Raleigh and Laura Rowley, director of life sciences development for NCBiotech.

Market Access

JP Morgan Week 2025 – Jeff Fischer

White Papers

Spotlight on

Life Sciences Industry Report Part 1 Download

Life Sciences Industry Report 2025

In pharmaphorum’s inaugural Life Sciences Industry Report 2025, delve into the trends that propelled the pharmaceutical industry along in 2024.

Market Access

Sponsored

Navigating Routes to Commercial Excellence in Cell and Gene ...

'Navigating Routes to Commercial Success in Cell and Gene Therapy', authored by Franjo Hanzl, VP, Business Development, Commercial at EVERSANA, Dr.

Debates & Insight

Sponsored

Pricing & Market Access Outlook 2015/2016 Edition

Pricing and market access (P&MA) are key issues for the pharma industry as healthcare budgets continue to tighten and the value of innovative drugs, particularly in areas of high unmet need

Event

Market Access

Partner Content

Targeted Therapies Partnering & Licensing Summit Asia

Accelerate Licensing & Co-Development in Asia: Providing Pharma De-Risked Assets to Fuel Pipelines Faster, & Biotech Access to International Partnersh

Market Access

Partner Content

Measuring Patient Engagement Summit Europe

The World’s Only Patient Engagement Measurement Summit is coming to Europe!

Market Access

Partner Content

The Inaugural Market Access for CNS Therapeutics Summit Has ...

The only dedicated forum focused on tackling the unique commercial and reimbursement challenges facing treatments for neurodegeneration...

Market Access

Sponsored

Innovative contracting in Europe – a Trojan horse?

Overview

Market Access

Sponsored

Launch excellence in a disrupted world – challenges & opport...

Overview

Market Access

Sponsored

Orphan medicines launch excellence: sustaining launch succes...

Overview Launching orphan medicines excellently will become even more important over the next five years as more patients with rare diseases have pharmacotherapies available.

Partner Content

Market Access

Partner Content

Targeted Therapies Partnering & Licensing Summit Asia

Accelerate Licensing & Co-Development in Asia: Providing Pharma De-Risked Assets to Fuel Pipelines Faster, & Biotech Access to International Partnersh

Market Access